Regulatory polymorphisms modulate the expression of HLA class II molecules and promote autoimmunity

  1. Prithvi Raj
  2. Ekta Rai
  3. Ran Song
  4. Shaheen Khan
  5. Benjamin E Wakeland
  6. Kasthuribai Viswanathan
  7. Carlos Arana
  8. Chaoying Liang
  9. Bo Zhang
  10. Igor Dozmorov
  11. Ferdicia Carr-Johnson
  12. Mitja Mitrovic
  13. Graham B Wiley
  14. Jennifer A Kelly
  15. Bernard R Lauwerys
  16. Nancy J Olsen
  17. Chris Cotsapas
  18. Christine K Garcia
  19. Carol A Wise
  20. John B Harley
  21. Swapan K Nath
  22. Judith A James
  23. Chaim O Jacob
  24. Betty P Tsao
  25. Chandrashekhar Pasare
  26. David R Karp
  27. Quan Zhen Li
  28. Patrick M Gaffney
  29. Edward K Wakeland  Is a corresponding author
  1. University of Texas Southwestern Medical Center, United States
  2. Yale School of Medicine, United States
  3. Oklahoma Medical Research Foundation, United States
  4. Université catholique de Louvain, Belgium
  5. Penn State Medical School, United States
  6. Texas Scottish Rite Hospital for Children, United States
  7. Cincinnati Children's Hospital Medical Center, United States
  8. University of Southern California, United States
  9. University of California, Los Angeles, United States

Abstract

Targeted sequencing of sixteen SLE risk loci among 1349 Caucasian cases and controls produced a comprehensive dataset of the variations causing susceptibility to systemic lupus erythematosus (SLE). Two independent disease association signals in the HLA-D region identified two regulatory regions containing 3562 polymorphisms that modified thirty-seven transcription factor binding sites. These extensive functional variations are a new and potent facet of HLA polymorphism. Variations modifying the consensus binding motifs of IRF4 and CTCF in the XL9 regulatory complex modified the transcription of HLA-DRB1, HLA-DQA1 and HLA-DQB1 in a chromosome-specific manner, resulting in a 2.5-fold increase in the surface expression of HLA-DR and DQ molecules on dendritic cells with SLE risk genotypes, which increases to >4-fold after stimulation. Similar analyses of fifteen other SLE risk loci identified 1206 functional variants tightly linked with disease-associated SNPs and demonstrated that common disease alleles contain multiple causal variants modulating multiple immune system genes.

Article and author information

Author details

  1. Prithvi Raj

    Department of Immunology, University of Texas Southwestern Medical Center, Dallas, United States
    Competing interests
    The authors declare that no competing interests exist.
  2. Ekta Rai

    Department of Immunology, University of Texas Southwestern Medical Center, Dallas, United States
    Competing interests
    The authors declare that no competing interests exist.
  3. Ran Song

    Department of Immunology, University of Texas Southwestern Medical Center, Dallas, United States
    Competing interests
    The authors declare that no competing interests exist.
  4. Shaheen Khan

    Department of Immunology, University of Texas Southwestern Medical Center, Dallas, United States
    Competing interests
    The authors declare that no competing interests exist.
  5. Benjamin E Wakeland

    Department of Immunology, University of Texas Southwestern Medical Center, Dallas, United States
    Competing interests
    The authors declare that no competing interests exist.
  6. Kasthuribai Viswanathan

    Department of Immunology, University of Texas Southwestern Medical Center, Dallas, United States
    Competing interests
    The authors declare that no competing interests exist.
  7. Carlos Arana

    Department of Immunology, University of Texas Southwestern Medical Center, Dallas, United States
    Competing interests
    The authors declare that no competing interests exist.
  8. Chaoying Liang

    Department of Immunology, University of Texas Southwestern Medical Center, Dallas, United States
    Competing interests
    The authors declare that no competing interests exist.
  9. Bo Zhang

    Department of Immunology, University of Texas Southwestern Medical Center, Dallas, United States
    Competing interests
    The authors declare that no competing interests exist.
  10. Igor Dozmorov

    Department of Immunology, University of Texas Southwestern Medical Center, Dallas, United States
    Competing interests
    The authors declare that no competing interests exist.
  11. Ferdicia Carr-Johnson

    Department of Immunology, University of Texas Southwestern Medical Center, Dallas, United States
    Competing interests
    The authors declare that no competing interests exist.
  12. Mitja Mitrovic

    Department of Neurology, Yale School of Medicine, New Haven, United States
    Competing interests
    The authors declare that no competing interests exist.
  13. Graham B Wiley

    Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, United States
    Competing interests
    The authors declare that no competing interests exist.
  14. Jennifer A Kelly

    Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, United States
    Competing interests
    The authors declare that no competing interests exist.
  15. Bernard R Lauwerys

    Pole de pathologies rhumatismales, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain, Bruxelles, Belgium
    Competing interests
    The authors declare that no competing interests exist.
  16. Nancy J Olsen

    Division of Rheumatology, Department of Medicine, Penn State Medical School, Hershey, United States
    Competing interests
    The authors declare that no competing interests exist.
  17. Chris Cotsapas

    Department of Neurology, Yale School of Medicine, New Haven, United States
    Competing interests
    The authors declare that no competing interests exist.
  18. Christine K Garcia

    Eugene McDermott Center for Human Growth and Development, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, United States
    Competing interests
    The authors declare that no competing interests exist.
  19. Carol A Wise

    Sarah M. and Charles E. Seay Center for Musculoskeletal Research, Texas Scottish Rite Hospital for Children, Dallas, United States
    Competing interests
    The authors declare that no competing interests exist.
  20. John B Harley

    Cincinnati VA Medical Center, Cincinnati Children's Hospital Medical Center, Cincinnati, United States
    Competing interests
    The authors declare that no competing interests exist.
  21. Swapan K Nath

    Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, United States
    Competing interests
    The authors declare that no competing interests exist.
  22. Judith A James

    Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, United States
    Competing interests
    The authors declare that no competing interests exist.
  23. Chaim O Jacob

    Department of Medicine, University of Southern California, Los Angeles, United States
    Competing interests
    The authors declare that no competing interests exist.
  24. Betty P Tsao

    Department of Medicine, University of California, Los Angeles, Los Angeles, United States
    Competing interests
    The authors declare that no competing interests exist.
  25. Chandrashekhar Pasare

    Department of Immunology, University of Texas Southwestern Medical Center, Dallas, United States
    Competing interests
    The authors declare that no competing interests exist.
  26. David R Karp

    Rheumatic Diseases Division, Department of Medicine, University of Texas Southwestern Medical Center, Dallas, United States
    Competing interests
    The authors declare that no competing interests exist.
  27. Quan Zhen Li

    Department of Immunology, University of Texas Southwestern Medical Center, Dallas, United States
    Competing interests
    The authors declare that no competing interests exist.
  28. Patrick M Gaffney

    Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, United States
    Competing interests
    The authors declare that no competing interests exist.
  29. Edward K Wakeland

    Department of Immunology, University of Texas Southwestern Medical Center, Dallas, United States
    For correspondence
    edward.wakeland@utsouthwestern.edu
    Competing interests
    The authors declare that no competing interests exist.

Ethics

Human subjects: All the study subjects gave their written informed consent for the study. All the research protocols and methods employed were approved by UT Southwestern Institutional Review Board.

Copyright

© 2016, Raj et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 4,888
    views
  • 1,115
    downloads
  • 113
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Prithvi Raj
  2. Ekta Rai
  3. Ran Song
  4. Shaheen Khan
  5. Benjamin E Wakeland
  6. Kasthuribai Viswanathan
  7. Carlos Arana
  8. Chaoying Liang
  9. Bo Zhang
  10. Igor Dozmorov
  11. Ferdicia Carr-Johnson
  12. Mitja Mitrovic
  13. Graham B Wiley
  14. Jennifer A Kelly
  15. Bernard R Lauwerys
  16. Nancy J Olsen
  17. Chris Cotsapas
  18. Christine K Garcia
  19. Carol A Wise
  20. John B Harley
  21. Swapan K Nath
  22. Judith A James
  23. Chaim O Jacob
  24. Betty P Tsao
  25. Chandrashekhar Pasare
  26. David R Karp
  27. Quan Zhen Li
  28. Patrick M Gaffney
  29. Edward K Wakeland
(2016)
Regulatory polymorphisms modulate the expression of HLA class II molecules and promote autoimmunity
eLife 5:e12089.
https://doi.org/10.7554/eLife.12089

Share this article

https://doi.org/10.7554/eLife.12089

Further reading

    1. Developmental Biology
    2. Genetics and Genomics
    Svanhild Nornes, Susann Bruche ... Sarah De Val
    Research Article

    The establishment and growth of the arterial endothelium requires the coordinated expression of numerous genes. However, regulation of this process is not yet fully understood. Here, we combined in silico analysis with transgenic mice and zebrafish models to characterize arterial-specific enhancers associated with eight key arterial identity genes (Acvrl1/Alk1, Cxcr4, Cxcl12, Efnb2, Gja4/Cx37, Gja5/Cx40, Nrp1 and Unc5b). Next, to elucidate the regulatory pathways upstream of arterial gene transcription, we investigated the transcription factors binding each arterial enhancer compared to a similar assessment of non-arterial endothelial enhancers. These results found that binding of SOXF and ETS factors was a common occurrence at both arterial and pan-endothelial enhancers, suggesting neither are sufficient to direct arterial specificity. Conversely, FOX motifs independent of ETS motifs were over-represented at arterial enhancers. Further, MEF2 and RBPJ binding was enriched but not ubiquitous at arterial enhancers, potentially linked to specific patterns of behaviour within the arterial endothelium. Lastly, there was no shared or arterial-specific signature for WNT-associated TCF/LEF, TGFβ/BMP-associated SMAD1/5 and SMAD2/3, shear stress-associated KLF4 or venous-enriched NR2F2. This cohort of well characterized and in vivo-verified enhancers can now provide a platform for future studies into the interaction of different transcriptional and signalling pathways with arterial gene expression.

    1. Genetics and Genomics
    Sophie Debaenst, Tamara Jarayseh ... Andy Willaert
    Research Article

    Heritable fragile bone disorders (FBDs), ranging from multifactorial to rare monogenic conditions, are characterized by an elevated fracture risk. Validating causative genes and understanding their mechanisms remain challenging. We assessed a semi-high throughput zebrafish screening platform for rapid in vivo functional testing of candidate FBD genes. Six genes linked to severe recessive osteogenesis imperfecta (OI) and four associated with bone mineral density (BMD) from genome-wide association studies were analyzed using CRISPR/Cas9-based crispant screening in F0 mosaic founder zebrafish. Next-generation sequencing confirmed high indel efficiency (mean 88%), mimicking stable knock-out models. Skeletal phenotyping at 7, 14, and 90 days post-fertilization (dpf) using microscopy, Alizarin Red S staining, and microCT was performed. Larval crispants showed variable osteoblast and mineralization phenotypes, while adult crispants displayed consistent skeletal defects, including malformed neural and haemal arches, vertebral fractures and fusions, and altered bone volume and density. In addition, aldh7a1 and mbtps2 crispants experienced increased mortality due to severe skeletal deformities. RT-qPCR revealed differential expression of osteogenic markers bglap and col1a1a, highlighting their biomarker potential. Our results establish zebrafish crispant screening as a robust tool for FBD gene validation, combining skeletal and molecular analyses across developmental stages to uncover novel insights into gene functions in bone biology.